OBJECTIVE: To evaluate the epidemiology of the human papillomavirus (HPV) type and correlate it with the Papanicolaou smears in human immunodeficiency virus-seropositive women in Johannesburg, South Africa. STUDY DESIGN: In a cohort of 148 women, HPV DNA testing was performed with the Roche HPV genotyping test (Branchburg, New Jersey, U.S.A). Papanicolaou smears were performed by standard cytology utilizing 2001 Bethesda reporting guidelines. RESULTS: The average age and CD4 count of the participants was 35 years and 255 cells per mm3, respectively. Fifty-four percent had abnormal Papanicolaou smears; 66% of the abnormal cytology was low grade changes, with 33% assessed as having high grade changes. HPV DNA was found in 95% of the 148 subjects assessed, with 83% having 1 or more HPV oncogenic types. Common oncogenic types were 16, 35, 53 and 18. When HPV results were stratified by CD4, there was a significant risk of an oncogenic HPV type in women with CD4 <200. Significant odds ratios for high grade lesions were seen in HPV types 16, 35, 51, 66, 69 and 73. CONCLUSION: The results of HPV typing illustrate the diverse range of oncogenic HPV and high prevalence of oncogenic type. These results highlight the need for improved access to Papanicolaou smear screening for this population.
OBJECTIVE: To evaluate the epidemiology of the human papillomavirus (HPV) type and correlate it with the Papanicolaou smears in human immunodeficiency virus-seropositive women in Johannesburg, South Africa. STUDY DESIGN: In a cohort of 148 women, HPV DNA testing was performed with the Roche HPV genotyping test (Branchburg, New Jersey, U.S.A). Papanicolaou smears were performed by standard cytology utilizing 2001 Bethesda reporting guidelines. RESULTS: The average age and CD4 count of the participants was 35 years and 255 cells per mm3, respectively. Fifty-four percent had abnormal Papanicolaou smears; 66% of the abnormal cytology was low grade changes, with 33% assessed as having high grade changes. HPV DNA was found in 95% of the 148 subjects assessed, with 83% having 1 or more HPV oncogenic types. Common oncogenic types were 16, 35, 53 and 18. When HPV results were stratified by CD4, there was a significant risk of an oncogenic HPV type in women with CD4 <200. Significant odds ratios for high grade lesions were seen in HPV types 16, 35, 51, 66, 69 and 73. CONCLUSION: The results of HPV typing illustrate the diverse range of oncogenic HPV and high prevalence of oncogenic type. These results highlight the need for improved access to Papanicolaou smear screening for this population.
Authors: D M Cerqueira; D de S Moraes; G N L Camara; F A Amaral; C N R Oyama; M Q C dos Santos; C R F Martins Journal: Arch Virol Date: 2006-08-04 Impact factor: 2.574
Authors: Marcia L Shew; J Dennis Fortenberry; Wanzhu Tu; Beth E Juliar; Byron E Batteiger; Brahim Qadadri; Darron R Brown Journal: Arch Pediatr Adolesc Med Date: 2006-02
Authors: Jennifer R Moodley; Margaret Hoffman; Henri Carrara; Bruce R Allan; Diane D Cooper; Lynn Rosenberg; Lynette E Denny; Samuel Shapiro; Anna-Lise Williamson Journal: BMC Cancer Date: 2006-05-23 Impact factor: 4.430
Authors: V V Sahasrabuddhe; M H Mwanahamuntu; S H Vermund; W K Huh; M D Lyon; J S A Stringer; G P Parham Journal: Br J Cancer Date: 2007-04-17 Impact factor: 7.640
Authors: Pragna Patel; Charles E Rose; Pamela Y Collins; Bernardo Nuche-Berenguer; Vikrant V Sahasrabuddhe; Emmanuel Peprah; Susan Vorkoper; Sonak D Pastakia; Dianne Rausch; Naomi S Levitt Journal: AIDS Date: 2018-07-01 Impact factor: 4.177
Authors: Alexander M Strasak; Georg Goebel; Hans Concin; Ruth M Pfeiffer; Larry J Brant; Gabriele Nagel; Willi Oberaigner; Nicole Concin; Günter Diem; Elfriede Ruttmann; Ulrike Gruber-Moesenbacher; Felix Offner; Alfonso Pompella; Karl P Pfeiffer; Hanno Ulmer Journal: Cancer Res Date: 2010-04-13 Impact factor: 12.701
Authors: Hilary K Whitham; Stephen E Hawes; Haitao Chu; J Michael Oakes; Alan R Lifson; Nancy B Kiviat; Papa Salif Sow; Geoffrey S Gottlieb; Selly Ba; Marie P Sy; Shalini L Kulasingam Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-05-17 Impact factor: 4.254
Authors: R A Hanisch; P S Sow; M Toure; A Dem; B Dembele; P Toure; R L Winer; J P Hughes; G S Gottlieb; Q Feng; N B Kiviat; S E Hawes Journal: J Clin Virol Date: 2013-10-18 Impact factor: 3.168
Authors: Jenell S Coleman; Michelle S Cespedes; Susan Cu-Uvin; Rose J Kosgei; May Maloba; Jean Anderson; Timothy Wilkin; Antoine Jaquet; Julia Bohlius; Kathryn Anastos; Kara Wools-Kaloustian Journal: J Low Genit Tract Dis Date: 2016-01 Impact factor: 1.925